Health · Ai
Vivace Therapeutics, Inc.
Vivace Therapeutics is a San Mateo, California oncology company turning novel Hippo-YAP pathway biology into first-in-class cancer drugs. Its lead small molecule, VT3989, is a first-in-class YAP/TEAD inhibitor that blocks TEAD auto-palmitoylation and has shown durable responses in treatment-resistant mesothelioma and NF2-mutant tumors. Built on a capital-efficient US-China 'virtual biotech' model, the company has raised roughly $105 million across four rounds and is preparing a registrational Phase 3 trial.